Streptococcal C5a peptidase vaccine
AssigneeRegents of the University of Minnesota
InventorPaul Patrick Cleary
Life of this patent
Estimating the term…
Abstract
Novel vaccines for use against .beta.-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of streptococcal C5a peptidase, or a fragment or mutant thereof. Also disclosed is a method of protecting a susceptible mammal against .beta.-hemolytic Streptococcus colonization or infection by administering such a vaccine.
Claims19
A vaccine comrising an immunogenic amount of an enzymatically inactive streptococcal C5a peptidase (SCP), which amount is effective to reduce the incidence of or protect against .beta.-hemolytic Streptococcus colonization or infection in a susceptible mammal in combination with a physiologically-acceptable, non toxic vehicle.
A method of protecting a susceptible mammal against .beta.-hemolytic Streptoccocus colonization or infection comprising administering to said mammal an effective amount of a vaccine comprising an immunogenic amount of an enzymatically inactive streptococcal C5a peptidase (SCP), which amount is effective to reduce the incidence of or protect against Streptococcus colonization or infection in said susceptible mammal in combination with a physiologically-acceptable, non toxic vehicle.
Dependencies are inferred from the claim text.